Friday, July 10, 2026

pharma · Dravet Syndrome · Dravet syndrome · STOK

Stoke Therapeutics

Stoke Therapeutics is a pharma organization headquartered in Bedford, USA. It trades on NYSE under ticker STOK. Primary therapeutic focus areas include Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy,

Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
Status
Public
HQ
Bedford, USA
Founded
2017
Employees
205
Programs
8
Drugs
4
Patents
14
Clinical program

Pethidine

Approved · small molecule · Pain Relief in Labour

Pethidine for Pain Relief in Labour is a Approved program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).

← All Stoke Therapeutics projects Approved small molecule completed

Internal code RG_12-151

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Stoke Therapeutics
Phase
Approved
Modality
small_molecule
Indication
Pain Relief in Labour
Status
completed
Trials
1

Clinical trials